Megan Srongprapa Dahler, PA-C | |
300 Tower Rd Ne Ste 200, Marietta, GA 30060-9403 | |
(770) 427-5717 | |
Not Available |
Full Name | Megan Srongprapa Dahler |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 300 Tower Rd Ne Ste 200, Marietta, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932773983 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 10372 (Georgia) | Secondary |
363A00000X | Physician Assistant | 10372 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Megan Srongprapa Dahler, PA-C 300 Tower Rd Ne Ste 200, Marietta, GA 30060-9403 Ph: (770) 427-5717 | Megan Srongprapa Dahler, PA-C 300 Tower Rd Ne Ste 200, Marietta, GA 30060-9403 Ph: (770) 427-5717 |
News Archive
Colgate-Palmolive Company, the world leader in oral care, announced this week that it has reached 100 million children in the United States, providing free dental screenings, oral health education and treatment referrals as part of its ongoing national education program Colgate Bright Smiles, Bright Futures®.
Cord Blood America, Inc., announced today its stem cell processing and storage subsidiary, CorCell, is launching "Afford-A-Cord," which reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service. The Afford-A-Cord program will be offered as an additional payment option to CorCell's long standing traditional payment programs.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.
Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve.
› Verified 5 days ago